Compositions for the transdermal delivery of pharmaceutical actives
US5026556A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 10, 1988 |
| Grant date | Jun 25, 1991 |
| Priority date | — |
| Expiry date | Nov 10, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions for the transdermal delivery of buprenorphine comprising a safe and effective amount of buprenorphine in a carrier comprising: PA1 (a) a polar solvent material selected from the group consisting of C.sub.3 -C.sub.4 diols, C.sub.3 -C.sub.6 triols, and mixtures thereof; and PA0 (b) a polar lipid material selected from the group consisting of fatty alcohol esters, fatty acid esters, and mixtures thereof; wherein said polar solvent material and said polar lipid material are present in a weight ratio of solvent material:lipid material of from about 60:40 to about 99:1. Preferably, the polar solvent material is propylene glycol, and the polar lipid material is an ester of a C.sub.8 -C.sub.12 fatty alcohol or fatty acid. Particularly preferred polar lipid materials include methyl laurate and methyl caprylate. The ratio of polar solvent material to polar lipid material is preferably from about 90:10 to about 98:2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.